COVID-19 Resource Center

COVID-19 Resource Center

April 02, 2020
1 min read

FDA clears IND application for natural killer cell-based COVID-19 therapy

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The FDA cleared an investigational new drug application for CYNK-001 for the treatment of adults with COVID-19 infection, according to the agent’s manufacturer.

CYNK-001 (Celularity) is an investigational, cryopreserved, allogeneic natural killer cell therapy derived from placental hematopoietic stem cells.

"This investigational new drug application represents a significant step toward a potential treatment of patients infected with COVID-19 virus, which is spreading globally at unanticipated rates," Robert Hariri, MD, PhD, founder, chairman and CEO of Celularity, said in a company-issued statement.

"With our initial clinical study, we will gain an understanding of the impact CYNK-001 can have on patients recently diagnosed with COVID-19,” Hariri added. “We are hopeful to contribute to flattening the COVID-19 curve, expanding on the promising early results we've seen in our clinical studies in devastating cancers to patients with coronavirus."

This FDA clearance will allow Celularity to begin a phase 1/phase 2 clinical trial of its natural killer cell therapy in up to 86 patients with COVID-19. The investigational treatment is believed to be the first immunotherapy to receive this clearance by the FDA for treatment of COVID-19, according to the statement.

"Studies have established that there is robust activation of [natural killer] cells during viral infection regardless of the virus class," Xiaokui Zhang, PhD, chief scientific officer of Celularity, said in the statement.

Zhang said CYNK-001 has demonstrated “a range of biological activities” that would allow its cellular therapy to potentially recognize and kill infected cells.

“These functions suggest that CYNK-001 could provide a benefit to patients with COVID-19 in terms of limiting SARS-CoV-2 replication and disease progression by eliminating the infected cells,” he added.

The FDA approved an IND for CYNK-001 in January for the treatment of glioblastoma multiforme, a type of brain cancer, as previously reported by Healio.